Retatrutide is a research-grade compound supplied for laboratory use only.
Certificate of Analysis
Batch PA-0035 — 10mg
View COA
Research Grade Quality
Independently Tested
Retatrutide
$139.99
Size / Strength
HPLC Verified
COA Included
Fast Dispatch
Discreet Shipping
100% Quality Guarantee
Every batch of Retatrutide is independently third-party tested. 30-day money-back guarantee — no questions asked.
Retatrutide – Research Overview
Research Use Only
This product is intended solely for laboratory research purposes. Not for human consumption.
Retatrutide – Storage & Handling
Correct storage is essential for maintaining the stability and purity of Retatrutide. Follow the guidance below for both the lyophilised (freeze-dried) powder and any reconstituted solution.
- Store lyophilised powder at 2–8°C (refrigerated), protected from light
- For longer-term storage, keep frozen at -20°C in the original sealed vial
- Once reconstituted, refrigerate at 2–8°C and use within 30 days
- Avoid repeated freeze-thaw cycles once reconstituted
- Shelf life of 24 months from manufacture date when stored correctly
Retatrutide – Technical Specifications
Every batch of Retatrutide is independently analysed before dispatch. The values below describe the current research batch.
| Product Name | Retatrutide |
|---|---|
| CAS Number | 2381089-83-2 |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4731.33 g/mol |
| Quantity / Strength | 10mg | 20mg | 30mg | 40mg | 50mg |
| Purity | ≥ 99% (HPLC) |
| Form | Lyophilised Powder |
| Appearance | White Lyophilised Powder |
| Batch Number | PA-0035 |
| Storage Conditions | 2°C-8°C (Refrigerated) |
| Category | Weight Loss |
| Intended Use | Research Use Only — not for human consumption |
Retatrutide – Certificate of Analysis
Every batch of Retatrutide is independently tested before dispatch. View the full COA for the current batch below.
Certificate of Analysis (COA)
Batch Number PA-0035
≥ 99%
Purity
HPLC
Confirmed
Identity
Mass Spec
Pass
Heavy Metals
ICP-MS
Research Disclaimer
For Research Use Only — Not for Human Consumption
This content is provided for educational, scientific and research-information purposes only. It does not provide medical advice, treatment recommendations or personal dosage instructions. Available evidence concerning Retatrutide includes preclinical research and ongoing or completed clinical investigations. Further research is required to better understand its safety, pharmacology and potential efficacy for specific research applications.
- Not for human or veterinary use
- No claims are made regarding safety or efficacy in humans
- Must be handled with appropriate laboratory safety equipment
- Purchaser assumes all responsibility for legal, compliant use
References
5 sources- 1Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept. Cell Metabolism. 2022;34(9):1234-1247.e9.PubMed: https://pubmed.ncbi.nlm.nih.gov/35985340/
- 2Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.PubMed: https://pubmed.ncbi.nlm.nih.gov/37366315/
- 3Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA. The Lancet. 2023;402(10401):529-544.PubMed: https://pubmed.ncbi.nlm.nih.gov/37385280/
- 4Coskun T, Urva S, Roell WC, et al. Effects of Retatrutide on Body Composition in People with Type 2 Diabetes: A Substudy of a Phase 2, Double-Blind, Parallel-Group, Placebo-Controlled, Randomised Trial. The Lancet Diabetes & Endocrinology. 2025.PubMed: https://pubmed.ncbi.nlm.nih.gov/40609566/
- 5Australian Government, Therapeutic Goods Administration (TGA). Concerns Regarding the Public Health Risks Associated with Unapproved Peptide Products. Therapeutic Goods Administration. 2026.TGA: https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products
Citations are provided for research reference and open in a new tab. Listing a study does not imply it evaluated this specific product.
Retatrutide – Frequently Asked Questions
Researchers Also Purchase
Why Researchers Choose Us
Research-Grade Quality. Trusted by Researchers Across Australia.
Learn About Our QualityDiscreet Packaging
Fast Australia-Wide Delivery
Expert Support
30-Day Money Back